Aclaris Therapeutics, Inc. (ACRS) is preparing to release new clinical results for two of its lead immuno-inflammatory drug candidates, marking an important update in the company's biologic and oral inhibitor pipeline.
The company announced that it will provide full results from its Phase 1a single-and multiple-ascending-dose study of ATI-052- its anti-TSLP/IL-4R bispecific antibody- along with the lead indication selection for ATI-2138, an ITK/JAK3 inhibitor. Both updates will be shared before the U.S. financial markets open on April 28, 2026, at 8:30 AM EST.
ACRS has traded between $1.16 and $4.89 over the past year. The stock closed Monday's trading at $4.41, up 2.56%. During overnight trading, the stock traded at $4.55, up 3.17%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.